Target Information
General Information of This Target
Target ID | PATR0VPYPS |
|||||
---|---|---|---|---|---|---|
Target Name | Glucocorticoid receptor (NR3C1) |
|||||
Gene Name | NR3C1 |
|||||
Gene ID | ||||||
Synonym | GRL; Nuclear receptor subfamily 3 group C member 1 |
|||||
Sequence |
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR
LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK Click to Show/Hide
|
|||||
Family | the nuclear hormone receptor family |
|||||
Function |
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth.[Isoform Alpha]: Has transcriptional activation and repression activity. Mediates glucocorticoid-induced apoptosis. Promotes accurate chromosome segregation during mitosis. May act as a tumor suppressor. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression.[Isoform Beta]: Acts as a dominant negative inhibitor of isoform Alpha. Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed. Loses this transcription modulator function on its own. Has no hormone-binding activity. May play a role in controlling glucose metabolism by maintaining insulin sensitivity. Reduces hepatic gluconeogenesis through down-regulation of PEPCK in an isoform Alpha-dependent manner. Directly regulates STAT1 expression in isoform Alpha-independent manner.[Isoform Alpha-2]: Has lower transcriptional activation activity than isoform Alpha. Exerts a dominant negative effect on isoform Alpha trans-repression mechanism.[Isoform GR-P]: Increases activity of isoform Alpha.
Click to Show/Hide
|
|||||
Uniprot Entry | ||||||
HGNC ID | ||||||
KEGG ID |
Full List of The ADC Related to This Target
Phase 2
ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
---|---|---|---|---|---|---|
ABBV-3373 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 17 |
MP-Ala-Ala |
[1] | |
ABBV-154 |
Adalimumab |
TNF |
Glucocorticoid receptor modulator |
Formyl-Gly-Glu |
[2] |
Phase 1
ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
---|---|---|---|---|---|---|
ABBV-319 |
Anti-CD19 ABBV319 IgG1 mAb |
CD19 |
Proprietary GRM agonist |
Formyl-Ala-Ala |
[3] |
Clinical candidate
ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
---|---|---|---|---|---|---|
CD70-glucocorticoid ADC |
Undisclosed |
CD70 |
Fluticasone propionate |
Pyrophosphate linker |
[4] | |
Cymac-001 |
Undisclosed |
CD163 |
Dexamethasone |
Undisclosed |
[5] |
Investigative
ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
---|---|---|---|---|---|---|
Anti-TNF ADC 121 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 17 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 126 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 20 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 127 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 25 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 128 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 26 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 129 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 30 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 131 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 31 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 134 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 64 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 104 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 5 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 105 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 16 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 106 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 17 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 107 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 18 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 108 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 19 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 109 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 20 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 110 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 22 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 111 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 23 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 112 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 24 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 113 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 25 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 114 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 26 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 115 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 30 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 116 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 31 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 117 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 33 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 118 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 61 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 119 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 5 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 120 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 5 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 123 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 19 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 124 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 19 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 125 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 20 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 130 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 31 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 132 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 32 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 133 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 32 |
MP-Ala-Ala |
[6] | |
Anti-TNF ADC 135 |
Anti-TNF mAb alpha-TNF |
TNFRSF1A |
GRM cpd 63 |
MP-Ala-Ala |
[6] | |
Anti-PRLR-Ab-LP2-P12 |
Anti-PRLR mAb |
PRLR |
Budesonide derivative P12 |
DIBAC-suc-PEG4-Val-Cit-PAB |
[7] | |
Anti-PRLR-Ab-LP1-P3 |
Anti-PRLR mAb |
PRLR |
Budesonide derivative P3 |
DIBAC-suc-PEG4-Val-Cit-PAB |
[7] |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.